As a service to the Society for Immunotherapy of Cancer's (SITC) membership and the oncology community as a whole, SITC offers FREE, CME-certified online education on the topic of immunotherapy through Clinical Advances in Immuno-Oncology, a robust online learning center. Developed through a partnership with Medscape Oncology, this learning center is designed to provide education to oncologists in a variety of immunotherapy related topics beginning with immunology fundamentals and advancing to tumor-specific immunotherapy education. As a new addition, SITC has also partnered with Medscape to offer Patient Education activities for patients, caregivers, or those interested in learning more about specific types of cancer and how immunotherapy can be used for them. To access the patient education activities, please scroll to the bottom of the page!
To access each CME educational activity, click on the topics below. For more online education activities, please visit SITC Cancer Immunotherapy connectED.
Expanding the Treatment Possibilities in SCCHN: What Role Do Cancer Immunotherapies Have?November 29, 2017Drs Haddad, Bauman, and Mehra discuss the latest data as well as practicalities of using immunotherapy in SCCHN.Emerging Considerations in the Use of Immune Checkpoint Inhibitors: What is MSI?November 28, 2017Drs Overman and Sinicrope discuss the emergence of MSI-H: what it is, how it may be used to help guide treatment with immunotherapy.C.Metastatic Melanoma: What Would You Do?November 21, 2017Use patient and tumor characteristics to determine individualized treatment strategies for patients with melanoma.Treatment Algorithms in Melanoma: Past, Present, and FutureNovember 14, 2017Watch these experts discuss updates in the use of immunotherapy in melanoma, including novel approaches and immunotherapy in the adjuvant settingOptimizing Outcomes in Advanced NSCLCOctober 25, 2017Test your knowledge by helping manage this patient's newly diagnosed NSCLC.Continuing the Path Forward: Essential Concepts of Cancer Immunotherapy in 2017September 26, 2017Cutting-edge approaches to immunotherapy include targeting the inhibitory and stimulatory pathways and IDO, cellular therapy, and vaccines.Emerging Considerations in the Use of Immune Checkpoint Inhibitors: CRC August 14, 2017Drs. Bendell and Lee discuss the role of checkpoint inhibition in the management of patients with colorectal cancer.Optimizing Outcomes in mRCC: Finding the Balance of Immune InhibitionMay 30, 2017Drs. Atkins and Choueiri discuss the latest advances in the use of immunotherapy in patients with mRCC.State of the Art in HCC: Immune Checkpoint ModulationMarch 24, 2017Listen to 2 experts discuss the latest in immune checkpoint modulation in advanced HCC.
Management of Glioblastoma: Where Have We Been and Where Are We Going?March 23, 2017Leading experts discuss insights on advances in the treatment of glioblastoma.Patient Centered Care in HNSCCFebruary 17, 2017Drs. Robert Ferris and Laura Chow discuss some of the practicalities involved in treating patients with HNSCC with checkpoint inhibitors.
Determining the Best Treatment Algorithm for Patients with Head and Neck Cancer December 20, 2016 Experts discuss treatment strategies for one patient with recurrent HNSCC and one with locally advanced HNSCC.
Emerging Considerations in Immune Checkpoint Inhibitors: Esophago-Gastric CancerNovember 29, 2017Drs Janjigian and Kelly discuss the emerging role of immunotherapy in the treatment of advanced gastric and gastroesophageal junction cancer.Challenging Case Studies in Advanced HCC: What Would You Do?November 27, 2018Review the guideline-based treatment of patients with advanced HCC.Advanced Lung Cancers: What's on the Horizon?November 20, 2017Experts review the latest abstracts and developments in NSCLC, SCLC, mesothelioma, and brain metastases.The Emerging Role of Immunotherapy in Hodgkin LymphomaNovember 14, 2017Drs Ansell, Armand, and Diefenbach discuss the latest research into the use of checkpoint inhibition in Hodgkin lymphoma.
Back to the Basics: Clinical Immunology and Its Implications for Cancer CareAugust 17, 2017Dr David Munn reviews the basics of the immune system, including which parts are promising targets for cancer therapyCheckpoint Inhibitors in First-Line Advanced NSCLC: What Should You Know? August 14, 2017Learn about monotherapy and combination therapy options for patients eligible for first-line immunotherapy.
Biomarkers for Cancer Immunotherapy: Understanding Their Growing Role in TumorsMarch 29, 2017What are the implications for NSCLC, colorectal cancer, and other tumors?
March 29, 2017Dr. Jonathan Rosenberg reviews the latest evidence on the use of checkpoint inhibitors in bladder cancer.
The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in NSCLC January 18, 2017Learn about the use of checkpoint inhibitors in patients with NSCLC.
Strengthening Lung Cancer Team Connections to Improve Outcomes with Immunotherapy December 16, 2016 Watch as an oncologist, pharmacist, and nurse discuss challenges and best practices for working in a team environment.
Additional activities are available in our archive. While these activities are no longer CME-certified, they remain valuable resources for oncologists interested in learning more about cancer immunotherapy.
Is Immunotherapy Right for My Lung Cancer? November 8, 2016 This activity is for people with non-small cell lung cancer who want to learn more about why, how, and when their care team may consider using immunotherapy as part of their treatment.
Immunotherapy Side Effects: Talking With Your Melanoma Care Team November 8, 2016 This article is for people who are taking checkpoint inhibitor medicines for metastatic melanoma, their care partners, and others who want to learn about treatment side effects.
This message was posted by a user wishing to remain anonymous Hi All His is an attempt to find answers on the observed onset of effect on Opdivo / Nivolumab treatment. If you are a doctor having experience with this treatment I would be eager to hear ...
What's new in immuno-oncology? Discover the latest advancements in combination immunotherapy in this interview with James Gulley in which he provides insider details of the Phase I trial for M7824. www.oncology-central.com/2017/11/22/whats-new-immuno-oncology-interview-james-gulley/ ...
The publication yesterday of the first clinical guidelines by the Society for Immunotherapy of Cancer on management of side effects associated with immunotherapies really felt momentous. We've been talking about these issues for a couple of years ...
It was great seeing old friends again and meeting new ones at the 32 nd Annual Meeting & Pre-Conference Programs in National Harbor! We appreciate all who joined SITC for our most successful Annual Meeting yet and hope you had a great time learning, ...
Is Immunotherapy for Lung Cancer the Same Thing as Chemotherapy? October 20, 2016 This activity is for people with non-small cell lung cancer (NSCLC) who want to learn more about how immunotherapy differs from chemotherapy.
What Treatment Is Right for My Metastatic Melanoma? October 19, 2016 This article is for people who have metastatic melanoma, their care partners, and others who want to learn about immunotherapy.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org